Home › Myeloproliferative Neoplasms › Massachusetts › Boston
Myeloproliferative Neoplasms clinical trials in Boston, MA
14 studies for Myeloproliferative Neoplasms are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RecruitingPhase 2
- Dana-Farber Cancer Institute, Boston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
RecruitingPhase 1/2
- Dana-Farber Cancer Institute, Boston
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis
RecruitingPhase 1
- Mass General Brigham, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
RecruitingPhase 1Healthy volunteers welcome
- Brigham and Women's Hospital, Boston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
- Massachusetts General Hospital, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
RecruitingPhase 1
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
RecruitingPhase 1
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
- Dana Farber Cancer Institute, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RecruitingPhase 2
- Dana-Farber Cancer Institute, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RecruitingPhase 2Healthy volunteers welcome
- DFCI/BWH Brigham and Women's Hospital, Boston
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
Recruiting
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
Myeloproliferative Neoplasms trials in other cities
- Houston, TX16 studies
- New York City, NY15 studies
- Miami, FL10 studies
- Milwaukee, WI10 studies
- Baldwin Park, CA9 studies
- Seattle, WA9 studies
- Durham, NC9 studies
- Chicago, IL9 studies
- St. Louis, MO8 studies
- Cleveland, OH8 studies
- Birmingham, AL8 studies
- Columbus, OH8 studies
Other studies in Boston
- Breast Cancer110 studies
- Non-Small Cell Lung Cancer89 studies
- Cancer (all types)86 studies
- Colorectal Cancer63 studies
- Metastatic Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer60 studies
- Depression51 studies
- Endometrial Cancer50 studies
- Acute Myeloid Leukemia45 studies
- Pancreatic Cancer44 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.